These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 26341133)
1. Development of a three component complex to increase isoniazid efficacy against isoniazid resistant and nonresistant Mycobacterium tuberculosis. Manning T; Plummer S; Baker T; Wylie G; Clingenpeel AC; Phillips D Bioorg Med Chem Lett; 2015 Oct; 25(20):4621-7. PubMed ID: 26341133 [TBL] [Abstract][Full Text] [Related]
2. Structural measurements and cell line studies of the copper-PEG-Rifampicin complex against Mycobacterium tuberculosis. Manning T; Mikula R; Wylie G; Phillips D; Jarvis J; Zhang F Bioorg Med Chem Lett; 2015 Feb; 25(3):451-8. PubMed ID: 25575660 [TBL] [Abstract][Full Text] [Related]
3. Structural measurements and cell line studies of the copper– PEG–Amikacin complex against Mycobacterium tuberculosis. Manning T; Patel H; Wylie G; Phillips D; Jarvis J Bioorg Med Chem Lett; 2015 Dec; 25(24):5825-30. PubMed ID: 26577695 [TBL] [Abstract][Full Text] [Related]
4. The copper (II) ion as a carrier for the antibiotic capreomycin against Mycobacterium tuberculosis. Manning T; Mikula R; Lee H; Calvin A; Darrah J; Wylie G; Phillips D; Bythell BJ Bioorg Med Chem Lett; 2014 Feb; 24(3):976-82. PubMed ID: 24424129 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids. Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427 [TBL] [Abstract][Full Text] [Related]
6. Isoniazid derivatives and their anti-tubercular activity. Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains]. Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015 [TBL] [Abstract][Full Text] [Related]
8. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid. Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and antimycobacterial property of PEG-bis(INH) conjugates. Kakkar D; Tiwari AK; Chuttani K; Khanna A; Datta A; Singh H; Mishra AK Chem Biol Drug Des; 2012 Aug; 80(2):245-53. PubMed ID: 22515497 [TBL] [Abstract][Full Text] [Related]
11. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on Zomorodbakhsh S; Abbasian Y; Naghinejad M; Sheikhpour M Int J Nanomedicine; 2020; 15():5901-5909. PubMed ID: 32884258 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065 [TBL] [Abstract][Full Text] [Related]
13. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis. Nagel S; Streicher EM; Klopper M; Warren RM; Van Helden PD Curr Drug Metab; 2017; 18(11):1030-1039. PubMed ID: 29086682 [TBL] [Abstract][Full Text] [Related]
14. [Defining of gene mutations and minimal inhibitory concentrations in isoniazid resistant Mycobacterium tuberculosis isolates]. Yıldırım E; Uzun M Mikrobiyol Bul; 2017 Oct; 51(4):305-316. PubMed ID: 29153061 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis. Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy. Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and SEM studies of novel 1-indanyl isoniazid and hydrazide Schiff base derivatives as new anti-tubercular agents. Nazim U; Ali SI; Ishrat G; Hassan A; Ahmed M; Ali M; Ali Z; Noori MY Pak J Pharm Sci; 2020 May; 33(3):1095-1103. PubMed ID: 33191234 [TBL] [Abstract][Full Text] [Related]
18. Chemical disarming of isoniazid resistance in Flentie K; Harrison GA; Tükenmez H; Livny J; Good JAD; Sarkar S; Zhu DX; Kinsella RL; Weiss LA; Solomon SD; Schene ME; Hansen MR; Cairns AG; Kulén M; Wixe T; Lindgren AEG; Chorell E; Bengtsson C; Krishnan KS; Hultgren SJ; Larsson C; Almqvist F; Stallings CL Proc Natl Acad Sci U S A; 2019 May; 116(21):10510-10517. PubMed ID: 31061116 [No Abstract] [Full Text] [Related]
19. [Identification of trehalose-phosphate phosphatase associated with drug-resistance from culture supernatants of isoniazid-resistant Mycobacterium tuberculosis]. Yue J; Liu LR; Xie JP; Lei JQ; Liang L; Wang HH Zhonghua Jie He He Hu Xi Za Zhi; 2004 Oct; 27(10):687-9. PubMed ID: 16200872 [TBL] [Abstract][Full Text] [Related]
20. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil. Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]